Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines

Journal of Leukocyte Biology

Volumn 98, Issue 3, 2015, Pages 347-356

  Blok, Bastiaan A ^a,b,c   Arts, Rob J W ^a   van Crevel, Reinout ^a   Benn, Christine Stabell ^b,c   Netea, Mihai G ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b STATENS SERUM INSTITUT   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Heterologous immunity; Innate immune memory; Monocytes macrophages; NK cells; Vaccination

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; INFLUENZA VACCINE; MEASLES VACCINE; VACCINIA VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE; VACCINE;

DRUG MECHANISM; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; MORBIDITY; MORTALITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VACCINIA; ANIMAL; IMMUNOLOGY;

ANIMALS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC MEMORY; VACCINES;

EID: 84940654033     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.5RI0315-096R     Document Type: Review

References (128)

1. Takeuchi, O., Akira, S. (2010) Pattern recognition receptors and inflammation. Cell 140, 805-820.
2. Kawai, T., Akira, S. (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373-384.
3. Chang, J. T., Wherry, E. J., Goldrath, A. W. (2014) Molecular regulation of effector and memory T cell differentiation. Nat. Immunol. 15, 1104-1115.
4. Aaby, P., Kollmann, T. R., Benn, C. S. (2014) Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat. Immunol. 15, 895-899.
5. Netea, M. G., Quintin, J., van der Meer, J. W. (2011) Trained immunity: a memory for innate host defense. Cell Host Microbe 9, 355-361.
6. Quintin, J., Cheng, S. C., van der Meer, J. W., Netea, M. G. (2014) Innate immune memory: towards a better understanding of host defense mechanisms. Curr. Opin. Immunol. 29, 1-7.
7. Quintin, J., Saeed, S., Martens, J. H., Giamarellos-Bourboulis, E. J., Ifrim, D. C., Logie, C., Jacobs, L., Jansen, T., Kullberg, B. J., Wijmenga, C., Joosten, L. A., Xavier, R. J., van der Meer, J. W., Stunnenberg, H. G., Netea, M. G. (2012) Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 12, 223-232.
8. Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L. A., Ifrim, D. C., Saeed, S., Jacobs, C., van Loenhout, J., de Jong, D., Stunnenberg, H. G., Xavier, R. J., van der Meer, J. W., van Crevel, R., Netea, M. G. (2012) Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl. Acad. Sci. USA 109, 17537-17542.
9. Saeed, S., Quintin, J., Kerstens, H. H., Rao, N. A., Aghajanirefah, A., Matarese, F., Cheng, S. C., Ratter, J., Berentsen, K., van der Ent, M. A., Sharifi, N., Janssen-Megens, E. M., Ter Huurne, M., Mandoli, A., van Schaik, T., Ng, A., Burden, F., Downes, K., Frontini, M., Kumar, V., Giamarellos-Bourboulis, E. J., Ouwehand, W. H., van der Meer, J. W., Joosten, L. A., Wijmenga, C., Martens, J. H., Xavier, R. J., Logie, C., Netea, M. G., Stunnenberg, H. G. (2014) Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 345, 1251086.
10. Ifrim, D. C., Quintin, J., Joosten, L. A., Jacobs, C., Jansen, T., Jacobs, L., Gow, N. A., Williams, D. L., van der Meer, J. W., Netea, M. G. (2014) Trained immunity or tolerance: opposing functional programs induced in human monocytes after engagement of various pattern recognition receptors. Clin. Vaccine Immunol. 21, 534-545.
11. Finlay, D. K. (2012) Regulation of glucose metabolism in T cells: new insight into the role of Phosphoinositide 3-kinases. Front. Immunol. 3, 247.
12. Levine, A. J., Puzio-Kuter, A. M. (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340-1344.
13. Cheng, S. C., Quintin, J., Cramer, R. A., Shepardson, K. M., Saeed, S., Kumar, V., Giamarellos-Bourboulis, E. J., Martens, J. H., Rao, N. A., Aghajanirefah, A., Manjeri, G. R., Li, Y., Ifrim, D. C., Arts, R. J., van der Veer, B. M., Deen, P. M., Logie, C., O'Neill, L. A., Willems, P., van de Veerdonk, F. L., van der Meer, J. W., Ng, A., Joosten, L. A., Wijmenga, C., Stunnenberg, H. G., Xavier, R. J., Netea, M. G. (2014) mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345, 1250684.
14. Kleinnijenhuis, J., Quintin, J., Preijers, F., Benn, C. S., Joosten, L. A., Jacobs, C., van Loenhout, J., Xavier, R. J., Aaby, P., van der Meer, J. W., van Crevel, R., Netea, M. G. (2014) Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J. Innate Immun. 6, 152-158.
15. Benn, C. S., Netea, M. G., Selin, L. K., Aaby, P. (2013) A small jab-a big effect: nonspecific immunomodulation by vaccines. Trends Immunol. 34, 431-439.
16. Mangtani, P., Abubakar, I., Ariti, C., Beynon, R., Pimpin, L., Fine, P. E., Rodrigues, L. C., Smith, P. G., Lipman, M., Whiting, P. F., Sterne, J. A. (2014) Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin. Infect. Dis. 58, 470-480.
17. Netea, M. G., van Crevel, R. (2014) BCG-induced protection: effects on innate immune memory. Semin. Immunol. 26, 512-517.
18. Sylvester, R. J., van der Meijden, A. P., Lamm, D. L. (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168, 1964-1970.
19. Salem, A., Nofal, A., Hosny, D. (2013) Treatment of common and plane warts in children with topical viable bacillus Calmette-Guerin. Pediatr. Dermatol. 30, 60-63.
20. Metawea, B., El-Nashar, A. R., Kamel, I., Kassem, W., Shamloul, R. (2005) Application of viable bacille Calmette-Guérin topically as a potential therapeutic modality in condylomata acuminata: a placebocontrolled study. Urology 65, 247-250.
21. Nofal, A., Yosef, A., Salah, E. (2013) Treatment of recalcitrant warts with bacillus Calmette-Guérin: a promising new approach. Dermatol. Ther. (Heidelb.) 26, 481-485.
22. Pereira, L. I., Dorta, M. L., Pereira, A. J., Bastos, R. P., Oliveira, M. A., Pinto, S. A., Galdino, Jr., H., Mayrink, W., Barcelos, W., Toledo, V. P., Lima, G. M., Ribeiro-Dias, F. (2009) Increase of NK cells and proinflammatory monocytes are associated with the clinical improvement of diffuse cutaneous leishmaniasis after immunochemotherapy with BCG/Leishmania antigens. Am. J. Trop. Med. Hyg. 81, 378-383.
23. Rousseau, M. C., Parent, M. E., St-Pierre, Y. (2008) Potential health effects from non-specific stimulation of the immune function in early age: the example of BCG vaccination. Pediatr. Allergy Immunol. 19, 438-448.
24. Faustman, D. L., Wang, L., Okubo, Y., Burger, D., Ban, L., Man, G., Zheng, H., Schoenfeld, D., Pompei, R., Avruch, J., Nathan, D. M. (2012) Proof-of-concept, randomized, controlled clinical trial of bacillus- Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One 7, e41756.
25. Williams, Jr., C. A., Dubos, R. J. (1959) Studies on fractions of methanol extracts of tubercle bacilli. I. Fractions which increase resistance to infection. J. Exp. Med. 110, 981-1004.
26. Dubos, R. J., Schaedler, R. W. (1957) Effects of cellular constituents of mycobacteria on the resistance of mice to heterologous infections I. Protective effects. J. Exp. Med. 106, 703-717.
27. Fox, A. E., Evans, G. L., Turner, F. J., Schwartz, B. S., Blaustein, A. (1966) Stimulation of nonspecific resistance to infection by a crude cell wall preparation from Mycobacterium phlei. J. Bacteriol. 92, 1-5.
28. Weiss, D. W. (1960) Enhanced resistance of mice to infection with Pasteurella pestis following vaccination with fractions of phenol-killed tubercle bacilli. Nature 186, 1060-1061.
29. Weiss, D. W., Bonhag, R. S., Parks, J. A. (1964) Studies on the heterologous immunogenicity of a menthanol-insoluble fraction of attenuated tubercle bacilli (Bcg). I. Antimicrobial protection. J. Exp. Med. 119, 53-70.
30. Maddison, S. E., Chandler, F. W., Kagan, I. G. (1978) The effect of pretreatment with BCG on infection with Schistosoma mansoni in mice and monkeys. J. Reticuloendothel. Soc. 24, 615-628.
31. Ikeda, S., Negishi, T., Nishimura, C. (1985) Enhancement of nonspecific resistance to viral infection by muramyldipeptide and its analogs. Antiviral Res. 5, 207-215.
32. Fortier, A. H., Mock, B. A., Meltzer, M. S., Nacy, C. A. (1987) Mycobacterium bovis BCG-induced protection against cutaneous and systemic Leishmania major infections of mice. Infect. Immun. 55, 1707-1714.
33. Weiss, D. W., Bonhag, R. S., Deome, K. B. (1961) Protective activity of fractions of tubercle bacilli against isologous tumours in mice. Nature 190, 889-891.
34. Howard, J. G., Biozzi, G., Halpern, B. N., Stiffel, C., Mouton, D. (1959) The effect of Mycobacterium tuberculosis (BCG) infection on the resistance of mice to bacterial endotoxin and Salmonella enteritidis infection. Br. J. Exp. Pathol. 40, 281-290.
35. Halpern, B. N., Biozzi, G., Howard, J., Stiffel, C., Mouton, D. (1958) [Increase of the toxic power of killed Eberthella typhosa in rats inoculated with living BCG; relation between this increase of susceptibility and the functional state of the reticuloendothelial system]. C. R. Seances Soc. Biol. Fil. 152, 899-902.
36. Suter, E., Ullman, G. E., Hoffman, R. G. (1958) Sensitivity of mice to endotoxin after vaccination with BCG (bacillus Calmette-Guerin). Proc. Soc. Exp. Biol. Med. 99, 167-169.
37. Naeslund, C. (1931) Expérience de vaccination par le bcg dans la province du norrbotten (suède). Revue de la Tuberculose 12, 617-636.
38. Institut Pasteur (Paris France). (1932) Vaccination Préventive de la Tuberculose de l'Homme et des Animaux, par le BCG; Rapports et Documents, Provenant des Divers Pays, la France Exceptée, Transmis à l'Institut Pasteur en 1932, Masson, Paris.
39. Shann, F. (2010) The non-specific effects of vaccines. Arch. Dis. Child. 95, 662-667.
40. Shann, F. (2013) Nonspecific effects of vaccines and the reduction of mortality in children. Clin. Ther. 35, 109-114.
41. Garly, M. L., Martins, C. L., Balé, C., Baldé, M. A., Hedegaard, K. L., Gustafson, P., Lisse, I. M., Whittle, H. C., Aaby, P. (2003) BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine 21, 2782-2790.
42. Roth, A., Gustafson, P., Nhaga, A., Djana, Q., Poulsen, A., Garly, M. L., Jensen, H., Sodemann, M., Rodriques, A., Aaby, P. (2005) BCG vaccination scar associated with better childhood survival in Guinea- Bissau. Int. J. Epidemiol. 34, 540-547.
43. Kristensen, I., Aaby, P., Jensen, H. (2000) Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. BMJ 321, 1435-1438.
44. Moulton, L. H., Rahmathullah, L., Halsey, N. A., Thulasiraj, R. D., Katz, J., Tielsch, J. M. (2005) Evaluation of non-specific effects of infant immunizations on early infant mortality in a southern Indian population. Trop. Med. Int. Health 10, 947-955.
45. Hirve, S., Bavdekar, A., Juvekar, S., Benn, C. S., Nielsen, J., Aaby, P. (2012) Non-specific and sex-differential effects of vaccinations on child survival in rural western India. Vaccine 30, 7300-7308.
46. Aaby, P., Roth, A., Ravn, H., Napirna, B. M., Rodrigues, A., Lisse, I. M., Stensballe, L., Diness, B. R., Lausch, K. R., Lund, N., Biering-Sørensen, S., Whittle, H., Benn, C. S. (2011) Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J. Infect. Dis. 204, 245-252.
47. Biering-Sørensen, S., Aaby, P., Napirna, B. M., Roth, A., Ravn, H., Rodrigues, A., Whittle, H., Benn, C. S. (2012) Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact. Pediatr. Infect. Dis. J. 31, 306-308.
48. Stensballe, L. G., Nante, E., Jensen, I. P., Kofoed, P. E., Poulsen, A., Jensen, H., Newport, M., Marchant, A., Aaby, P. (2005) Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine 23, 1251-1257.
49. Roth, A. E., Benn, C. S., Ravn, H., Rodrigues, A., Lisse, I. M., Yazdanbakhsh, M., Whittle, H., Aaby, P. (2010) Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea- Bissau. BMJ 340, c671.
50. Gil, A., Kenney, L. L., Mishra, R., Watkin, L. B., Aslan, N., Selin, L. K. (2015) Vaccination and heterologous immunity: educating the immune system. Trans. R. Soc. Trop. Med. Hyg. 109, 62-69.
51. Mathurin, K. S., Martens, G. W., Kornfeld, H., Welsh, R. M. (2009) CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J. Virol. 83, 3528-3539.
52. Yang, H., Tompkins, W. A. (1983) Nonspecific cytotoxicity of vacciniainduced peritoneal exudates in hamsters is mediated by Thy-1.2 homologue-positive cells distinct from NK cells and macrophages. J. Immunol. 131, 2545-2550.
53. Lertmemongkolchai, G., Cai, G., Hunter, C. A., Bancroft, G. J. (2001) Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens. J. Immunol. 166, 1097-1105.
54. Berg, R. E., Cordes, C. J., Forman, J. (2002) Contribution of CD8+ T cells to innate immunity: IFN-gamma secretion induced by IL-12 and IL-18. Eur. J. Immunol. 32, 2807-2816.
55. Berg, R. E., Crossley, E., Murray, S., Forman, J. (2003) Memory CD8+ T cells provide innate immune protection against Listeria monocytogenes in the absence of cognate antigen. J. Exp. Med. 198, 1583-1593.
56. Hashiguchi, T., Oyamada, A., Sakuraba, K., Shimoda, K., Nakayama, K. I., Iwamoto, Y., Yoshikai, Y., Yamada, H. (2014) Tyk2-dependent bystander activation of conventional and nonconventional Th1 cell subsets contributes to innate host defense against Listeria monocytogenes infection. J. Immunol. 192, 4739-4747.
57. Hu, J., August, A. (2008) Naive and innate memory phenotype CD4+ T cells have different requirements for active Itk for their development. J. Immunol. 180, 6544-6552.
58. Sänger, C., Busche, A., Bentien, G., Spallek, R., Jonas, F., Böhle, A., Singh, M., Brandau, S. (2004) Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer. BMC Cancer 4, 86.
59. Andersen, A., Roth, A., Jensen, K. J., Erikstrup, C., Lisse, I. M., Whittle, H., Sartono, E., Yazdanbakhsh, M., Aaby, P., Benn, C. S. (2013) The immunological effect of revaccination with bacille Calmette-Guérin vaccine at 19 months of age. Vaccine 31, 2137-2144.
60. Ho, P., Wei, X., Seah, G. T. (2010) Regulatory T cells induced by Mycobacterium chelonae sensitization influence murine responses to bacille Calmette-Guerin. J. Leukoc. Biol. 88, 1073-1080.
61. Ota, M. O. C., Vekemans, J., Schlegel-Haueter, S. E., Fielding, K., Sanneh, M., Kidd, M., Newport, M. J., Aaby, P., Whittle, H., Lambert, P. H., McAdam, K. P., Siegrist, C. A., Marchant, A. (2002) Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J. Immunol. 168, 919-925.
62. Ritz, N., Mui, M., Balloch, A., Curtis, N. (2013) Non-specific effect of bacille Calmette-Guérin vaccine on the immune response to routine immunisations. Vaccine 31, 3098-3103.
63. Van 't Wout, J. W., Poell, R., van Furth, R. (1992) The role of BCG/PPDactivated macrophages in resistance against systemic candidiasis in mice. Scand. J. Immunol. 36, 713-719.
64. Maddison, S. E., Chandler, F. W., McDougal, J. S., Slemenda, S. B., Kagan, I. G. (1978) Schistosoma mansoni infection in intact and B cell deficient mice: the effect of pretreatment with BCG in these experimental models. Am. J. Trop. Med. Hyg. 27, 966-975.
65. Parra, M., Liu, X., Derrick, S. C., Yang, A., Tian, J., Kolibab, K., Kumar, S., Morris, S. L. (2013) Molecular analysis of non-specific protection against murine malaria induced by BCG vaccination. PLoS One 8, e66115.
66. Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L. A., Jacobs, C., Xavier, R. J., van der Meer, J. W., van Crevel, R., Netea, M. G. (2014) BCG-induced trained immunity in NK cells: Role for non-specific protection to infection. Clin. Immunol. 155, 213-219.
67. Semple, P. L., Watkins, M., Davids, V., Krensky, A. M., Hanekom, W. A., Kaplan, G., Ress, S. (2011) Induction of granulysin and perforin cytolytic mediator expression in 10-week-old infants vaccinated with BCG at birth. Clin. Dev. Immunol. 2011, ID 438463.
68. Jensen, K. J., Larsen, N., Biering-Sorensen, S., Andersen, A., Eriksen, H. B., Monteiro, I., Hougaard, D., Aaby, P., Netea, M. G., Flanagan, K. L., Benn, C. S. (2015) Heterologous immunological effects of early BCG vaccination in low-birth-weight infants in Guinea-Bissau: a randomized-controlled trial. J. Infect. Dis. 211, 956-967.
69. Suriano, F., Santini, D., Perrone, G., Amato, M., Vincenzi, B., Tonini, G., Muda, A., Boggia, S., Buscarini, M., Pantano, F. (2013) Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer. J. Exp. Clin. Cancer Res. 32, 87.
70. Alam, M. J., Rashid, M. M., Kabir, Y., Raqib, R., Ahmad, S. M. (2015) On birth single dose live attenuated OPV and BCG vaccination induces gut cathelicidin LL37 responses at 6 week of age: a natural experiment. Vaccine 33, 18-21.
71. Buffen, K., Oosting, M., Quintin, J., Ng, A., Kleinnijenhuis, J., Kumar, V., van de Vosse, E., Wijmenga, C., van Crevel, R., Oosterwijk, E., Grotenhuis, A. J., Vermeulen, S. H., Kiemeney, L. A., van de Veerdonk, F. L., Chamilos, G., Xavier, R. J., van der Meer, J. W., Netea, M. G., Joosten, L. A. (2014) Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. PLoS Pathog. 10, e1004485.
72. Patel, D., Simons, H. (2013) Yellow fever vaccination: is one dose always enough? Travel Med. Infect. Dis. 11, 266-273.
73. Campi-Azevedo, A. C., de Almeida Estevam, P., Coelho-Dos-Reis, J. G., Peruhype-Magalhães, V., Villela-Rezende, G., Quaresma, P. F., Maia, Mde. L., Farias, R. H., Camacho, L. A., Freire, Mda. S., Galler, R., Yamamura, A. M., Almeida, L. F., Lima, S. M., Nogueira, R. M., Silva Sá, G. R., Hokama, D. A., de Carvalho, R., Freire, R. A., Filho, E. P., Leal, Mda. L., Homma, A., Teixeira-Carvalho, A., Martins, R. M., Martins- Filho, O. A. (2014) Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect. Dis. 14, 391.
74. Fisker, A. B., Ravn, H., Rodrigues, A., Østergaard, M. D., Bale, C., Benn, C. S., Aaby, P. (2014) Co-administration of live measles and yellow fever vaccines and inactivated pentavalent vaccines is associated with increased mortality compared with measles and yellow fever vaccines only. An observational study from Guinea-Bissau. Vaccine 32, 598-605.
75. Silva, M. L., Martins, M. A., Espírito-Santo, L. R., Campi-Azevedo, A. C., Silveira-Lemos, D., Ribeiro, J. G., Homma, A., Kroon, E. G., Teixeira- Carvalho, A., El ói-Santos, S. M., Martins-Filho, O. A. (2011) Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine 29, 583-592.
76. Martins, M. A., Silva, M. L., Elói-Santos, S. M., Ribeiro, J. G., Peruhype- Magalhães, V., Marciano, A. P., Homma, A., Kroon, E. G., Teixeira- Carvalho, A., Martins-Filho, O. A. (2008) Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. Vaccine 26, 1173-1184.
77. Neves, P. C., Matos, D. C., Marcovistz, R., Galler, R. (2009) TLR expression and NK cell activation after human yellow fever vaccination. Vaccine 27, 5543-5549.
78. Tai, L. H., Zhang, J., Scott, K. J., de Souza, C. T., Alkayyal, A. A., Ananth, A. A., Sahi, S., Adair, R. A., Mahmoud, A. B., Sad, S., Bell, J. C., Makrigiannis, A. P., Melcher, A. A., Auer, R. C. (2013) Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells. Clin. Cancer Res. 19, 5104-5115.
79. Bruni, D., Chazal, M., Sinigaglia, L., Chauveau, L., Schwartz, O., Desprès, P., Jouvenet, N. (2015) Viral entry route determines how human plasmacytoid dendritic cells produce type I interferons. Sci. Signal. 8, ra25.
80. Cao, W., Manicassamy, S., Tang, H., Kasturi, S. P., Pirani, A., Murthy, N., Pulendran, B. (2008) Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycinsensitive PI(3)K-mTOR-p70S6K pathway. Nat. Immunol. 9, 1157-1164.
81. Gaucher, D., Therrien, R., Kettaf, N., Angermann, B. R., Boucher, G., Filali-Mouhim, A., Moser, J. M., Mehta, R. S., Drake III, D. R., Castro, E., Akondy, R., Rinfret, A., Yassine-Diab, B., Said, E. A., Chouikh, Y., Cameron, M. J., Clum, R., Kelvin, D., Somogyi, R., Greller, L. D., Balderas, R. S., Wilkinson, P., Pantaleo, G., Tartaglia, J., Haddad, E. K., Sékaly, R. P. (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205, 3119-3131.
82. Engelmann, F., Josset, L., Girke, T., Park, B., Barron, A., Dewane, J., Hammarlund, E., Lewis, A., Axthelm, M. K., Slifka, M. K., Messaoudi, I. (2014) Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model. PLoS Negl. Trop. Dis. 8, e3295.
83. Scherer, C. A., Magness, C. L., Steiger, K. V., Poitinger, N. D., Caputo, C. M., Miner, D. G., Winokur, P. L., Klinzman, D., McKee, J., Pilar, C., Ward, P. A., Gillham, M. H., Haulman, N. J., Stapleton, J. T., Iadonato, S. P. (2007) Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus, or upper respiratory infections. Vaccine 25, 6458-6473.
84. Querec, T. D., Akondy, R. S., Lee, E. K., Cao, W., Nakaya, H. I., Teuwen, D., Pirani, A., Gernert, K., Deng, J., Marzolf, B., Kennedy, K., Wu, H., Bennouna, S., Oluoch, H., Miller, J., Vencio, R. Z., Mulligan, M., Aderem, A., Ahmed, R., Pulendran, B. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116-125.
85. Klein, S. L., Jedlicka, A., Pekosz, A. (2010) The Xs and Y of immune responses to viral vaccines. Lancet Infect. Dis. 10, 338-349.
86. Couch, R. B. (2008) Seasonal inactivated influenza virus vaccines. Vaccine 26 (Suppl 4), D5-D9.
87. Leentjes, J., Kox, M., Stokman, R., Gerretsen, J., Diavatopoulos, D., Rimmelzwaan, G. F., Picckers, P., Netea M. G. (2015) BCG-vaccination enhances immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized placebo-controlled double-blind pilot study. J. Infect. Dis. [Epub ahead of print].
88. Mohanty, S., Joshi, S. R., Ueda, I., Wilson, J., Blevins, T. P., Siconolfi, B., Meng, H., Devine, L., Raddassi, K., Tsang, S., Belshe, R. B., Hafler, D. A., Kaech, S. M., Kleinstein, S. H., Trentalange, M., Allore, H. G., Shaw, A. C. (2015) Prolonged proinflammatory cytokine production in monocytes modulated by interleukin 10 after influenza vaccination in older adults. J. Infect. Dis. 11, 1174-1184.
89. Lanthier, P. A., Huston, G. E., Moquin, A., Eaton, S. M., Szaba, F. M., Kummer, L. W., Tighe, M. P., Kohlmeier, J. E., Blair, P. J., Broderick, M., Smiley, S. T., Haynes, L. (2011) Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses. Vaccine 29, 7849-7856.
90. Geeraedts, F., Goutagny, N., Hornung, V., Severa, M., de Haan, A., Pool, J., Wilschut, J., Fitzgerald, K. A., Huckriede, A. (2008) Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog. 4, e1000138.
91. Jost, S., Reardon, J., Peterson, E., Poole, D., Bosch, R., Alter, G., Altfeld, M. (2011) Expansion of 2B4+ natural killer (NK) cells and decrease in NKp46+ NK cells in response to influenza. Immunology 132, 516-526.
92. Kennedy, R. B., Ovsyannikova, I. G., Jacobson, R. M., Poland, G. A. (2009) The immunology of smallpox vaccines. Curr. Opin. Immunol. 21, 314-320.
93. Aaby, P., Gustafson, P., Roth, A., Rodrigues, A., Fernandes, M., Sodemann, M., Holmgren, B., Benn, C. S., Garly, M. L., Lisse, I. M., Jensen, H. (2006) Vaccinia scars associated with better survival for adults. An observational study from Guinea-Bissau. Vaccine 24, 5718-5725.
94. Jensen, M. L., Dave, S., Schim van der Loeff, M., da Costa, C., Vincent, T., Leligdowicz, A., Benn, C. S., Roth, A., Ravn, H., Lisse, I. M., Whittle, H., Aaby, P. (2006) Vaccinia scars associated with improved survival among adults in rural Guinea-Bissau. PLoS One 1, e101.
95. Lankes, H. A., Fought, A. J., Evens, A. M., Weisenburger, D. D., Chiu, B. C. (2009) Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study. Cancer Causes Control 20, 517-523.
96. Pfahlberg, A., Kölmel, K. F., Grange, J. M., Mastrangelo, G., Krone, B., Botev, I. N., Niin, M., Seebacher, C., Lambert, D., Shafir, R., Schneider, D., Kokoschka, E. M., Kleeberg, U. R., Uter, W., Gefeller, O. (2002) Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study. J. Invest. Dermatol. 119, 570-575.
97. Krone, B., Kölmel, K. F., Henz, B. M., Grange, J. M. (2005) Protection against melanoma by vaccination with bacille Calmette-Guerin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. Eur. J. Cancer 41, 104-117.
98. Yang, H., Cain, C. A., Woan, M. C., Tompkins, W. A. (1982) Evaluation of hamster natural cytotoxic cells and vaccinia-induced cytotoxic cells for Thy-1.2 homologue by using a mouse monoclonal α-Thy-1.2 antibody. J. Immunol. 129, 2239-2243.
99. Carpenter, E. A., Ruby, J., Ramshaw, I. A. (1994) IFN-gamma, TNF, and IL-6 production by vaccinia virus immune spleen cells. An in vitro study. J. Immunol. 152, 2652-2659.
100. Deng, L., Dai, P., Ding, W., Granstein, R. D., Shuman, S. (2006) Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells. J. Virol. 80, 9977-9987.
101. Yao, Y., Li, P., Singh, P., Thiele, A. T., Wilkes, D. S., Renukaradhya, G. J., Brutkiewicz, R. R., Travers, J. B., Luker, G. D., Hong, S. C., Blum, J. S., Chang, C. H. (2007) Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II. Cell. Immunol. 246, 92-102.
102. Schleupner, C. J., Glasgow, L. A. (1978) Peritoneal macrophage activation indicated by enhanced chemiluminescence. Infect. Immun. 21, 886-895.
103. Price, P. J., Torres-Domínguez, L. E., Brandmüller, C., Sutter, G., Lehmann, M. H. (2013) Modified vaccinia virus Ankara: innate immune activation and induction of cellular signalling. Vaccine 31, 4231-4234.
104. Yáñez, A., Hassanzadeh-Kiabi, N., Ng, M. Y., Megías, J., Subramanian, A., Liu, G. Y., Underhill, D. M., Gil, M. L., Goodridge, H. S. (2013) Detection of a TLR2 agonist by hematopoietic stem and progenitor cells impacts the function of the macrophages they produce. Eur. J. Immunol. 43, 2114-2125.
105. Bautista-L ópez, N., Ward, B. J., Mills, E., McCormick, D., Martel, N., Ratnam, S. (2000) Development and durability of measles antigenspecific lymphoproliferative response after MMR vaccination. Vaccine 18, 1393-1401.
106. Aaby, P., Martins, C. L., Garly, M. L., Balé, C., Andersen, A., Rodrigues, A., Ravn, H., Lisse, I. M., Benn, C. S., Whittle, H. C. (2010) Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. BMJ 341, c6495.
107. Aaby, P., Martins, C. L., Garly, M. L., Rodrigues, A., Benn, C. S., Whittle, H. (2012) The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy. BMJ Open 2, e000761.
108. Martins, C. L., Benn, C. S., Andersen, A., Balé, C., Schaltz-Buchholzer, F., Do, V. A., Rodrigues, A., Aaby, P., Ravn, H., Whittle, H., Garly, M. L. (2014) A randomized trial of a standard dose of Edmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions. J. Infect. Dis. 209, 1731-1738.
109. Bottomley, C., Bojang, A., Smith, P. G., Darboe, O., Antonio, M., Foster- Nyarko, E., Kampmann, B., Greenwood, B., D'Alessandro, U., Roca, A. (2015) The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study. Emerg. Themes Epidemiol. 12, 1.
110. Avota, E., Gassert, E., Schneider-Schaulies, S. (2010) Measles virusinduced immunosuppression: from effectors to mechanisms. Med. Microbiol. Immunol. (Berl.) 199, 227-237.
111. De Vries, R. D., McQuaid, S., van Amerongen, G., Yüksel, S., Verburgh, R. J., Osterhaus, A. D., Duprex, W. P., de Swart, R. L. (2012) Measles immune suppression: lessons from the macaque model. PLoS Pathog. 8, e1002885.
112. Hahm, B., Cho, J. H., Oldstone, M. B. (2007) Measles virus-dendritic cell interaction via SLAM inhibits innate immunity: selective signaling through TLR4 but not other TLRs mediates suppression of IL-12 synthesis. Virology 358, 251-257.
113. Indoh, T., Yokota, S., Okabayashi, T., Yokosawa, N., Fujii, N. (2007) Suppression of NF-kappaB and AP-1 activation in monocytic cells persistently infected with measles virus. Virology 361, 294-303.
114. Bieback, K., Lien, E., Klagge, I. M., Avota, E., Schneider-Schaulies, J., Duprex, W. P., Wagner, H., Kirschning, C. J., Ter Meulen, V., Schneider-Schaulies, S. (2002) Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J. Virol. 76, 8729-8736.
115. Tanabe, M., Kurita-Taniguchi, M., Takeuchi, K., Takeda, M., Ayata, M., Ogura, H., Matsumoto, M., Seya, T. (2003) Mechanism of upregulation of human Toll-like receptor 3 secondary to infection of measles virus-attenuated strains. Biochem. Biophys. Res. Commun. 311, 39-48.
116. Shingai, M., Ebihara, T., Begum, N. A., Kato, A., Honma, T., Matsumoto, K., Saito, H., Ogura, H., Matsumoto, M., Seya, T. (2007) Differential type I IFN-inducing abilities of wild-type versus vaccine strains of measles virus. J. Immunol. 179, 6123-6133.
117. Clifford, H. D., Yerkovich, S. T., Khoo, S. K., Zhang, G., Upham, J., Le Souëf, P. N., Richmond, P., Hayden, C. M. (2012) TLR3 and RIG-I gene variants: associations with functional effects on receptor expression and responses to measles virus and vaccine in vaccinated infants. Hum. Immunol. 73, 677-685.
118. Ovsyannikova, I. G., Reid, K. C., Jacobson, R. M., Oberg, A. L., Klee, G. G., Poland, G. A. (2003) Cytokine production patterns and antibody response to measles vaccine. Vaccine 21, 3946-3953.
119. Pabst, H. F., Spady, D. W., Carson, M. M., Stelfox, H. T., Beeler, J. A., Krezolek, M. P. (1997) Kinetics of immunologic responses after primary MMR vaccination. Vaccine 15, 10-14.
120. Hussey, G. D., Goddard, E. A., Hughes, J., Ryon, J. J., Kerran, M., Carelse, E., Strebel, P. M., Markowitz, L. E., Moodie, J., Barron, P., Latief, Z., Sayed, R., Beatty, D., Griffin, D. E. (1996) The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants. J. Infect. Dis. 173, 1320-1326.
121. Jensen, K. J., Søndergaard, M., Andersen, A., Sartono, E., Martins, C., Garly, M. L., Eugen-Olsen, J., Ullum, H., Yazdanbakhsh, M., Aaby, P., Benn, C. S., Erikstrup, C. (2014) A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects. PLoS One 9, e97536.
122. Colmenares, V., Noyola, D. E., Monsiváis-Urenda, A., Salgado- Bustamante, M., Estrada-Capetillo, L., González-Amaro, R., Baranda, L. (2012) Human papillomavirus immunization is associated with increased expression of different innate immune regulatory receptors. Clin. Vaccine Immunol. 19, 1005-1011.
123. Aaby, P., Garly, M. L., Nielsen, J., Ravn, H., Martins, C., Balé, C., Rodrigues, A., Benn, C. S., Lisse, I. M. (2007) Increased female-male mortality ratio associated with inactivated polio and diphtheria-tetanuspertussis vaccines: observations from vaccination trials in Guinea-Bissau. Pediatr. Infect. Dis. J. 26, 247-252.
124. Aaby, P., Benn, C., Nielsen, J., Lisse, I. M., Rodrigues, A., Ravn, H. (2012) Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries. BMJ Open 2, e000707.
125. Rodrigues, A., Fischer, T. K., Valentiner-Branth, P., Nielsen, J., Steinsland, H., Perch, M., Garly, M. L., Mølbak, K., Aaby, P. (2006) Community cohort study of rotavirus and other enteropathogens: are routine vaccinations associated with sex-differential incidence rates? Vaccine 24, 4737-4746.
126. Valentiner-Branth, P., Perch, M., Nielsen, J., Steinsland, H., Garly, M. L., Fischer, T. K., Sommerfelt, H., Mølbak, K., Aaby, P. (2007) Community cohort study of Cryptosporidium parvum infections: sex-differential incidences associated with BCG and diphtheria-tetanus-pertussis vaccinations. Vaccine 25, 2733-2741.
127. Fischer, J. E., Johnson, J. E., Johnson, T. R., Graham, B. S. (2000) Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection. J. Infect. Dis. 182, 1029-1038.
128. (2014) Meeting of the Strategic Advisory Group of Experts on immunization, April 2014-conclusions and recommendations. Wkly. Epidemiol. Rec. 89, 221-236.